A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has studied alterations in the KRAS gene in colorectal cancer by combining genomic ...
Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may play an important role in colon cancer. Researchers also showed how this ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
Lumakras plus Vectibix improved overall survival and response rates in KRAS G12C-mutated metastatic colorectal cancer, despite not achieving statistical significance. The combination showed a 30% ...
July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
A new preclinical study led by researchers at The University of Texas MD Anderson Cancer Center and Weill Cornell Medicine has uncovered genetic and cell-state adaptive mechanisms that drive ...
Tumor-informed versus tumor-agnostic ctDNA assays for molecular residual disease detection in colorectal cancer: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2026 ...
The authors of the publication, from left to right: Maria Navarro, PhD, former member of the CGE, IGTP, currently working at Ability Pharmaceuticals, Nuria Mulet, MD PhD (ICO, B-ARGO), Cinta Hierro, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results